AI Drug Discovery & Development Summit 2025

November 18-20, 2025
Boston, United States

The leading global event focused solely on AI in drug discovery and development

Your leading global event focused solely on AI in drug discovery is returning in 2025.

With deeper insights into target identification and target validation, and advanced sessions on AI-driven drug design, the event will now be adding dedicated content tracks for AI infrastructure, as well as a leadership forum on partnerships and business models and further expansion of the “women in AI” series. With new case studies, interactive workshops, and expanded networking opportunities, this year’s summit will be bigger and more impactful than ever.

Join us in Boston on November 18-20, 2025, as we push the boundaries of AI-driven drug discovery. We can’t wait to see you there!

Register your interest

2025 Featured Speakers

Peter Clark

Peter Clark

VP, Computational Drug Design

Novo Nordisk

Peter Clark

Peter Clark

VP, Computational Drug Design
Novo Nordisk

Claire Zhao

Claire Zhao

Associate Director, AI/ML & Quantitative & Digital Sciences

PFIZER

Claire Zhao

Claire Zhao

Associate Director, AI/ML & Quantitative & Digital Sciences
PFIZER

Zoran Krunic

Zoran Krunic

Principal Product Manager

Amgen

Zoran Krunic

Zoran Krunic

Principal Product Manager
Amgen

Since joining Amgen R&D in 2018, Zoran Krunic has been at the forefront of applying Machine Learning to enhance patient outcomes and streamline clinical trial enrollment processes, utilizing comprehensive Electronic Health Records and clinical datasets. His pioneering work in the Quantum Machine Learning space, in collaboration with IBM's Quantum team, has been instrumental in integrating machine learning with quantum computing through IBM’s Qiskit platform.

Prior to his tenure at Amgen, Zoran developed Machine Learning algorithms at Optum to predict hardware and software failures within complex enterprise architectures. He has a strong background in data engineering and systems development, having contributed significantly to large-scale projects at renowned organizations such as Capital Group and ARCO Petroleum.

In his current full and part-time endeavors, Zoran is leading the efforts in embracing generative AI technologies, with a particular focus on OpenAI's GPT and Anthropic's Claude-2 models. His work is focused on prompt engineering and its application to code generation, advanced document analysis, and process management, with a commitment to ethical AI practices and data privacy.

A recognized voice in quantum computing circles, Zoran is a regular presenter at industry conferences and has served on numerous panels discussing the integration of quantum computing and generative AI within the Health Sciences sector.

With a Master of Science in Electrical Engineering & Computer Science, Zoran continues to explore and contribute to the evolving relationship between quantum computing and artificial intelligence, fostering groundbreaking advancements in healthcare technology.

Chirag Sacher

Chirag Sacher

Director, Portfolio Innovation

Novartis

Chirag Sacher

Chirag Sacher

Director, Portfolio Innovation
Novartis

Ari Allyn-Feuer

Ari Allyn-Feuer

Director, AI Product

GSK

Ari Allyn-Feuer

Ari Allyn-Feuer

Director, AI Product
GSK

Mark Adams

Mark Adams

Venture Capital Partner

Two Bear Capital

Mark Adams

Mark Adams

Venture Capital Partner
Two Bear Capital

Petrina Kamya

Petrina Kamya

Global Head, AI Platforms, VP Insilico Medicine & President

Insilico Medicine

Petrina Kamya

Petrina Kamya

Global Head, AI Platforms, VP Insilico Medicine & President
Insilico Medicine

Arvind Rao

Arvind Rao

Associate Professor, Computational Medicine & Bioinformatics

University of Michigan

Arvind Rao

Arvind Rao

Associate Professor, Computational Medicine & Bioinformatics
University of Michigan

Jackie Hunter

Jackie Hunter

CEO

OI Pharma Partners

Jackie Hunter

Jackie Hunter

CEO
OI Pharma Partners

Zhiyong (Sean) Xie

Zhiyong (Sean) Xie

VP & Head, AI & Data Science

Xellarbio

Zhiyong (Sean) Xie

Zhiyong (Sean) Xie

VP & Head, AI & Data Science
Xellarbio

Adam Root

Adam Root

VP & Head, Protein Sciences

Generate Biomedicines

Adam Root

Adam Root

VP & Head, Protein Sciences
Generate Biomedicines

Ethan Pickering

Ethan Pickering

Head, Data Science & ML Research

Bayer

Ethan Pickering

Ethan Pickering

Head, Data Science & ML Research
Bayer

0+

Industry Experts

0+

Industry Leading Speakers

0

Main Event Days

0

Pre-Day Workshop

Who Attends

Attendees Include...

Balancing AI's Promises and Challenges

Balancing AI's Promises and Challenges

AI is transforming drug discovery, showing promise in preclinical research, but clinical success is still a challenge.

The Importance of Data Quality and Sharing for AI

The Importance of Data Quality and Sharing for AI

High-quality, diverse data is essential for effective AI. Data-sharing ensures inclusivity and accuracy.

The Power of Collaboration in AI-Driven Drug Development

The Power of Collaboration in AI-Driven Drug Development

Cross-functional collaboration is crucial for AI-driven drugdevelopment to tackle challenges and maximize AI's potential.

Quantum Computing and AI in Drug Discovery

Quantum Computing and AI in Drug Discovery

Quantum computing and autonomous systems, combined with AI, are unlocking new possibilities in drug discovery.

  • “The AI in Drug Discovery Summit was a thought-provoking meeting of the minds across disciplines!”

    — AstraZeneca

  • “I really enjoyed attending the Summit. It was well-organized with interesting topics, panel discussions, and great opportunities to network. I look forward to attending again!”

    — Benevolent AI

  • “The role of Artificial Intelligence in drug discovery and development is rapidly evolving. The AI Driven Drug Discovery Summit is a chance for participants to come up to speed across a range of areas, and interact with other stakeholders across the discipline.”

    — Two Bear Capital

  • “The AI Driven Drug Discovery Summit offered excellent insights from both pharma and commercial AI efforts that are difficult to find outside of an event like this.”

    — Qiagen

  • “This was a great opportunity to connect closely with practitioners in the AI drug discovery space. The quality of presentations, speakers, and panels was high, and it's really great to hear what different groups are doing at the forefront of our industry.”

    — Nobias Therapeutics

  • “I found the conference to be comprehensive, delving into various facets of AI applications in drug discovery, ranging from target identification to the analysis of clinical trial data. The speakers provided valuable insights, and I gained a wealth of knowledge from their presentations. Additionally, the event afforded me the opportunity to network with experts in the field, further enhancing my understanding and connections within this dynamic industry.”

    — Mariana Oncology

  • “This is a great place to meet people from pharma, biotech, and Venture Capital to see the use cases and trend of AI applications in drug discovery.”

    — Xellar Biosystems

  • “The AI Driven Drug Discovery Summit was an incredible experience, filled with inspiring discussions and valuable connections. I’m excited to return this year and dive deeper into the latest trends and innovations in AI Drug discovery.”

    — Fusion Fund

  • “I'm excited to speak at the 3rd Annual AI Driven Drug Discovery Summit in Boston! AI for biological discovery is still in its early days and we have so much to learn. I'm eager to share my perspective and engage with fellow innovators and thought leaders, as we collectively harness the transformative potential of AI to advance biological discovery and design.”

    — Bayer

2025 Partners